Research on the mutant prevention concentration of tigecycline for Klebsiella pneumoniae
10.16718/j.1009-7708.2017.06.006
- VernacularTitle:替加环素对肺炎克雷伯菌的防耐药突变浓度研究
- Author:
Xue ZHONG
1
;
Dongke CHEN
;
Hongtao XU
;
Wanyu FENG
Author Information
1. 北京大学人民医院药剂科,北京100044
- Keywords:
tigecycline;
Klebsiella pneumoniae;
mutant prevention concentration
- From:
Chinese Journal of Infection and Chemotherapy
2017;17(6):643-647
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the potential tigecycline resistance of Klebsiella pneumoniae during treatment.Methods The minimum inhibitory concentrations (MICs) and the mutant prevention concentrations (MPCs) of tigecycline were determined for K.pneumoniae isolates with four different resistant profiles.Corr.elations between MICs and MPCs were analyzed.We combined with the pharmacokinetic parameters of tigecycline to estimate the potential of emerging resistance to tigecycline monotherapy in K.pneumoniae.Results The MPCs of tigecycline for the carbapenem-and fluoroquinolone-resistant isolates were found to be 8-fold higher than those for carbapenem-and quinolones-susceptible isolates.Our data showed that the MPCs range and MPC90 values of tigecycline were 4-512 mg/L and 64 mg/L,respectively,which were much higher than the therapeutic concentrations of tigecycline in serum and tissues.Conclusions Long-term tigecycline monotherapy may predispose the emergence of resistance in K.pneumoniae,which is not recommended.It is desirable to carry out ongoing monitoring of K.pneumoniae susceptibility and tigecycline treatment effect.
